See more : Qomolangma Acquisition Corp. (QOMOR) Income Statement Analysis – Financial Results
Complete financial analysis of Hubei Goto Biopharm Co.,Ltd. (300966.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hubei Goto Biopharm Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- EnSilica plc (ENSI.L) Income Statement Analysis – Financial Results
- Airbus SE (AIR.PA) Income Statement Analysis – Financial Results
- Mirati Therapeutics, Inc. (MRTX) Income Statement Analysis – Financial Results
- Guangdong Land Holdings Limited (0124.HK) Income Statement Analysis – Financial Results
- TAJGVK Hotels & Resorts Limited (TAJGVK.NS) Income Statement Analysis – Financial Results
Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
About Hubei Goto Biopharm Co.,Ltd.
Hubei Goto Biopharm Co.,Ltd. engages in the production and sale of steroid hormone API's and intermediates in China. It offers starting materials, such as 9a-hydroxy-4-androstenedione(9a-OHAD), bisnoralcohol(BA), sitolactone, 1.4-androstadienedione(ADD), and 4-androstenedione(4-AD); intermediates, including estrogens, progesterone, nonsteroids, other hormones, and corticosteroids; and other pharmaceutical raw materials. The company was founded in 2006 and is based in Yicheng, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 566.40M | 604.57M | 590.89M | 468.12M | 464.80M | 437.30M | 333.69M |
| Cost of Revenue | 450.29M | 466.35M | 434.97M | 361.49M | 333.11M | 306.33M | 231.70M |
| Gross Profit | 116.11M | 138.22M | 155.91M | 106.62M | 131.69M | 130.98M | 101.99M |
| Gross Profit Ratio | 20.50% | 22.86% | 26.39% | 22.78% | 28.33% | 29.95% | 30.56% |
| Research & Development | 38.10M | 45.15M | 37.12M | 21.60M | 26.06M | 27.10M | 23.46M |
| General & Administrative | 16.76M | 15.08M | 18.53M | -6.12M | -40.60M | -29.60M | -14.63M |
| Selling & Marketing | 4.18M | 4.91M | 5.47M | 3.45M | 4.47M | 4.27M | 3.34M |
| SG&A | 54.61M | 19.98M | 24.00M | -2.66M | -36.14M | -25.33M | -11.29M |
| Other Expenses | 3.87M | -389.83K | 23.41M | 10.06M | 36.66M | 31.96M | 19.09M |
| Operating Expenses | 96.58M | 85.29M | 83.47M | 40.70M | 38.84M | 44.29M | 39.99M |
| Cost & Expenses | 546.87M | 551.64M | 518.45M | 402.20M | 371.96M | 350.62M | 271.69M |
| Interest Income | 2.13M | 1.92M | 1.19M | 1.28M | 2.26M | 3.13M | 1.97M |
| Interest Expense | 13.55M | 13.37M | 5.17M | 13.50M | 23.34M | 23.97M | 19.26M |
| Depreciation & Amortization | 28.21M | 30.06M | 23.36M | 21.18M | 17.03M | 15.15M | 9.62M |
| EBITDA | 60.51M | 79.12M | 116.39M | 88.18M | 104.77M | 100.33M | 69.11M |
| EBITDA Ratio | 10.68% | 13.71% | 20.07% | 20.60% | 27.57% | 27.58% | 25.98% |
| Operating Income | 19.53M | 38.90M | 62.71M | 57.30M | 79.69M | 78.33M | 55.21M |
| Operating Income Ratio | 3.45% | 6.43% | 10.61% | 12.24% | 17.15% | 17.91% | 16.55% |
| Total Other Income/Expenses | -413.68K | -389.83K | 23.41M | 2.94M | 3.12M | 2.05M | 432.18K |
| Income Before Tax | 19.12M | 38.51M | 86.12M | 60.24M | 82.81M | 80.39M | 55.64M |
| Income Before Tax Ratio | 3.38% | 6.37% | 14.57% | 12.87% | 17.82% | 18.38% | 16.67% |
| Income Tax Expense | -2.17M | -982.33K | 8.05M | 7.05M | 9.81M | 9.71M | 8.20M |
| Net Income | 23.01M | 40.21M | 78.33M | 53.29M | 73.00M | 70.68M | 47.44M |
| Net Income Ratio | 4.06% | 6.65% | 13.26% | 11.38% | 15.70% | 16.16% | 14.22% |
| EPS | 0.20 | 0.35 | 0.68 | 0.46 | 0.63 | 0.84 | 1.03 |
| EPS Diluted | 0.20 | 0.35 | 0.68 | 0.46 | 0.63 | 0.84 | 1.03 |
| Weighted Avg Shares Out | 115.03M | 115.28M | 115.28M | 115.28M | 115.28M | 84.14M | 46.06M |
| Weighted Avg Shares Out (Dil) | 115.03M | 115.28M | 115.28M | 115.28M | 115.28M | 84.14M | 46.06M |
Source: https://incomestatements.info
Category: Stock Reports